Jazz Pharmaceuticals plc
JAZZ
Market Cap$6.51B
Close$
$249.48
132.9% upside
Current Fair Value
132.9% upsideUndervalued by 132.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.51 Billion |
|---|---|
| Enterprise Value | $10.10 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $9.06 |
| Beta | 0.33 |
| Outstanding Shares | 60,979,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 13.6 |
|---|---|
| PEG | 2.55 |
| Price to Sales | 1.62 |
| Price to Book Ratio | 1.58 |
| Enterprise Value to Revenue | 2.48 |
| Enterprise Value to EBIT | 16.99 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.54 |
| Debt to Equity | 1.31 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Jazz Pharmaceuticals plc
1,210 employeesJazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...